UCB   Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3 Phase 4
Founded: Brussels Belgium (1928)

Organization Overview

First Clinical Trial
2016
NCT05028127
First Marketed Drug
1955
amphetamine (Adderall)
First NDA Approval
1984
chlorpheniramine
Last Known Activity
2021

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

001 844 599 22733 (UCB) | 001 844 599 2273 (UCB) | +1 844 599 2273 (UCB) | +1-844-599-2273 (UCB) | 1-844-599-2273(UCB) | +1 877 822 9493 (UCB) | 1 877 822 9493 (UCB) | 1-877-822-9493 (UCB) | UCB (+1 844 599 2273) | UCB (+1 877 822 9493) | UCB (+1 887 822 9493) | UCB Biopharma S.P.R.L. | UCB Biopharma SRL | UCB Celltech | UCB / Global Medical Affairs | UCB INC | UCB Japan Co. Ltd. | UCB Nordic A/S | UCB Pharma | UCB Pharma GmbH | UCB Pharma SA | UCB S.A. - Pharma Sector | UCB Trading (Shanghai) Co. Ltd. | UCB Young Investigator Research Program | WHITBY